Women and GLP-1 Side Effects: Does Sex Affect GI Tolerability?

Are women more likely to experience nausea, vomiting, constipation, or other gastrointestinal side effects from GLP-1 medications?

WEIGHT MANAGEMENT

Sarina Helton, MSN, APRN, FNP-C, CAE-OM

10/3/20264 min read

a pink flamingo standing on top of a lush green field
a pink flamingo standing on top of a lush green field

The answer right now is:

Possibly, but the evidence is not consistent enough to say that women are inherently more likely to experience GLP-1 side effects.

Some studies have identified female sex as a potential risk factor, while others have found no meaningful association or even different patterns.

This is an interesting area of emerging research, but it needs to be interpreted carefully.

What Did the 2024 Study Find?

A 2024 study evaluated 855 adults with type 2 diabetes who were starting treatment with a GLP-1 receptor agonist.

Researchers looked for factors that might predict gastrointestinal adverse effects.

After adjusting for other variables, female sex was associated with approximately 2.3 times the odds of developing gastrointestinal adverse effects compared with male sex.

Other factors identified in the study included:

  • Increasing age

  • A history of gastrointestinal disorders

  • Taking a greater number of other oral medications

This suggests that biological sex may influence GLP-1 tolerability.

But one study does not establish that women are universally more susceptible.

Other Studies Have Found Different Results

A large pharmacovigilance analysis of semaglutide-associated gastrointestinal adverse events found a different pattern.

Researchers evaluated 5,442 cases of semaglutide-associated GI adverse events reported to the FDA Adverse Event Reporting System.

Women accounted for more of the reported cases than men, but when researchers specifically compared serious versus non-serious gastrointestinal events, sex was not significantly associated with severity.

Instead, age and body weight were significantly different between serious and non-serious cases, while sex was not.

Interestingly, the association between semaglutide and reported gastrointestinal disorders remained present when researchers analyzed men and women separately.

So although more reports involved women, that does not necessarily mean women were biologically more susceptible to severe GI effects.

Why Are Pharmacovigilance Studies Different?

This is an important distinction.

Pharmacovigilance databases such as the FDA Adverse Event Reporting System are extremely useful for identifying potential medication safety signals after medications enter widespread use.

But they cannot tell us the true incidence of a side effect in women compared with men.

Why?

Because these databases contain reports, not a controlled population.

The number of reports can be influenced by:

  • How many women versus men use the medication

  • Differences in prescribing patterns

  • Differences in why the medication is being prescribed

  • Differences in reporting behavior

  • Differences in healthcare utilization

  • Media attention

  • Missing demographic information

Therefore, seeing more reports from women does not automatically mean that being female caused the increased reporting.

Why Might Sex Matter?

There are several biologically plausible reasons sex could influence medication tolerability, but we do not yet have enough evidence to identify one definitive mechanism for GLP-1 gastrointestinal side effects.

Potential contributors could include differences in:

  • Gastrointestinal motility

  • Gastric emptying

  • Hormonal signaling

  • Body composition

  • Drug exposure and pharmacokinetics

  • Gut-brain signaling

  • Baseline prevalence of certain gastrointestinal conditions

There may also be differences unrelated to biology, including medication utilization and adverse-event reporting.

At this point, these possibilities are better viewed as areas for continued research rather than explanations we can confidently apply to an individual patient.

So Are Women More Likely to Get Sick on GLP-1 Medications?

We don't know that.

It would be too strong to say:

"Women are more likely to get sick on GLP-1 medications."

A more accurate interpretation is:Sex may influence susceptibility to gastrointestinal side effects, but current research is inconsistent and sex alone is not a reliable way to predict who will tolerate treatment well.

A woman may have virtually no gastrointestinal symptoms.

A man may have significant nausea or vomiting.

Individual factors frequently matter more than sex alone.

Click Here to Learn why GLP-1 medications cause nausea.

What May Matter More Than Sex?

When assessing someone's likelihood of developing gastrointestinal side effects, it makes sense to look at the entire clinical picture.

Factors that may deserve consideration include:

  • Previous gastrointestinal problems

  • Current medications

  • Age

  • Dose

  • How quickly the dose is increased

  • Eating patterns

  • Hydration

  • Other medical conditions

  • Previous response to GLP-1 treatment

The medication itself also matters. Semaglutide, tirzepatide, liraglutide, and other incretin-based therapies are not identical medications.

What This Means for Women Taking a GLP-1

Being female is not a reason to avoid GLP-1 treatment.

It also doesn't mean you should expect to experience nausea or other gastrointestinal problems.

Instead, the emerging research reinforces something that applies to everyone receiving GLP-1 treatment:

Treatment should be individualized.

Pay attention to how you respond when treatment begins and when your dose changes.

If significant symptoms develop, they should be addressed rather than dismissed as something you're simply expected to tolerate.

The Takeaway

Some research suggests women may have a higher likelihood of developing GLP-1-related gastrointestinal side effects.

Other research has not confirmed that relationship.

That means we should resist turning an interesting statistical association into a clinical rule.

Sex may influence GLP-1 tolerability, but we do not currently understand the relationship well enough to use sex alone to predict who will experience gastrointestinal side effects.

Your individual medical history, medications, gastrointestinal health, treatment response, and dosing strategy provide a much more complete picture.

Medical Disclaimer

This information is provided for general educational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment. Individual responses to GLP-1 medications vary, and treatment decisions should be based on your medical history, medications, treatment goals, and individual risks and benefits.

Do not change your medication dose or dosing schedule without discussing it with your prescribing healthcare professional.

Seek medical attention for severe, persistent, or rapidly worsening symptoms.

References

Gao R, Li Y, Li A, et al. Risk factor screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs. Front Endocrinol (Lausanne). 2024;15:1502050. doi:10.3389/fendo.2024.1502050.

Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996179. doi:10.3389/fpubh.2022.996179.


Ready to Start Your Weight Management Journey?

GLP-1 medications can be powerful tools, but the right medication, dose, and rate of dose escalation can be different for each person.

At Optima Vida Healthcare, weight management is individualized based on your health history, previous treatments, response to medication, side effects, goals, and long-term needs.

Treatment may include GLP-1 or other weight-management medications when medically appropriate, along with ongoing monitoring and support.

Start Your Weight Management Evaluation →

Or Visit www.ovhmed.com for more information.